Teva Responds to Pfizer Motion to SCC to Amend or Re-hear

 

(Wikimedia)

I wrote recently about Pfizer's unusual  motion to the Supreme Court of Canada to amend its judgment or to re-hear the Viagra patent case regarding the Court's declaration that the '446 patent is void in rem. Pfizer's material can be found on my earlier posting here.

TEVA filed its response on November 26, 2012 which is available here.

The Canadian Generic Pharmaceutical Association (CGPA) response is here.

HPK